Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

News Focus

LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Voyageur Pharmaceuticals Ltd VYYRF

Primary Symbol: V.VM

Healthcare Drug Manufacturers - Specialty & Generic

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX... see more

Recent & Breaking News (TSXV:VM)

Voyageur Pharmaceuticals Ltd Announces Deferred Share Unit (DSU) Grant to Directors

TheNewsWire December 21, 2023

Voyageur Pharmaceuticals Ltd and Rain Cage Carbon Inc, Announce Breakthrough in Imaging Technology with Vanadium Fullerene Molecule

TheNewsWire December 21, 2023

Voyageur Pharmaceuticals kickstarts international expansion

Jocelyn Aspa December 14, 2023

Voyageur Pharmaceuticals Initiates International Expansion

TheNewsWire December 14, 2023

Voyageur Pharmaceuticals Achieves Milestone in the Development of HDXBa Barium Contrast Media

TheNewsWire September 14, 2023

Voyageur Pharmaceuticals Ltd. Announces Filing of Interim Financial Statements, Director Changes and Grant of Stock Options

TheNewsWire August 1, 2023

Voyageur Pharmaceuticals Ltd. Announces DSU Grants

TheNewsWire July 13, 2023

Discovery of a generation: The molecule that can enhance any industry

Jonathon Brown June 28, 2023

Voyageur Pharmaceuticals Publishes White Paper, SmoothX: A Promising New Positive Oral Contrast Agent That Enhances Patient Satisfaction and Diagnostic Excellence in CT Imaging

TheNewsWire June 12, 2023

The Canadian-made ground-breaking radiopharmaceutical breakthrough

Jonathon Brown June 6, 2023

Advancing environmental work at the Frances Creek barium project

Jonathon Brown May 31, 2023

Voyageur Pharmaceuticals Ltd. Advances with Environmental Field Work at Frances Creek Project Site For Notice of Work & Quarry Permitting

TheNewsWire May 31, 2023

Voyageur Pharmaceuticals Partners with Rain Cage Carbon to Revolutionize Medical Imaging with Nanocarbon-Based Contrast Drugs

TheNewsWire May 24, 2023

Voyageur Pharmaceuticals Ltd. Files Interim Financial Statements and Grants Deferred Share Units

TheNewsWire April 28, 2023

Voyageur (TSXV:VM) confirms preference for SmoothX in comparative studies

Trevor Abes April 11, 2023

Voyageur Pharmaceuticals Ltd. Completes Comparative Studies of its SmoothX(R) Contrast Media Confirming Product Superiority, and announces Option Grant and AGM Date

TheNewsWire April 4, 2023

Voyageur Pharmaceuticals Ltd. Files Annual Audited Financial Statements

TheNewsWire March 30, 2023

Voyageur Pharmaceuticals Ltd. Provides an Update and Prepares to Launch Initial Sales in Canada

TheNewsWire February 14, 2023

Voyageur Pharmaceuticals Ltd. Announces Issuance of Shares for Debt

TheNewsWire January 27, 2023

Amended: Voyageur Pharmaceuticals Ltd. Announces Final Closing of Increased Private Placement

TheNewsWire January 23, 2023